Structured Review

Agilent technologies antibodies anti p53
Immunohistochemical analysis of <t>p53</t> expression. (a) Moderate, diffuse staining in basal and suprabasal cells in squamous metaplasia; (b) weak, focal staining in mild dysplasia; (c) strong staining in a mucinous type ITAC, with weak/moderate staining in adjacent immature metaplasia and seromucous glands; (d) details of (c). H E staining, original magnification 200x (a, b, and d) and 100x (c).
Antibodies Anti P53, supplied by Agilent technologies, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/antibodies anti p53/product/Agilent technologies
Average 86 stars, based on 1 article reviews
Price from $9.99 to $1999.99
antibodies anti p53 - by Bioz Stars, 2021-04
86/100 stars

Images

1) Product Images from "Benign Lesions in Mucosa Adjacent to Intestinal-Type Sinonasal Adenocarcinoma"

Article Title: Benign Lesions in Mucosa Adjacent to Intestinal-Type Sinonasal Adenocarcinoma

Journal: Pathology Research International

doi: 10.4061/2011/230147

Immunohistochemical analysis of p53 expression. (a) Moderate, diffuse staining in basal and suprabasal cells in squamous metaplasia; (b) weak, focal staining in mild dysplasia; (c) strong staining in a mucinous type ITAC, with weak/moderate staining in adjacent immature metaplasia and seromucous glands; (d) details of (c). H E staining, original magnification 200x (a, b, and d) and 100x (c).
Figure Legend Snippet: Immunohistochemical analysis of p53 expression. (a) Moderate, diffuse staining in basal and suprabasal cells in squamous metaplasia; (b) weak, focal staining in mild dysplasia; (c) strong staining in a mucinous type ITAC, with weak/moderate staining in adjacent immature metaplasia and seromucous glands; (d) details of (c). H E staining, original magnification 200x (a, b, and d) and 100x (c).

Techniques Used: Immunohistochemistry, Expressing, Staining

2) Product Images from "Radiotherapy resistance acquisition in Glioblastoma. Role of SOCS1 and SOCS3"

Article Title: Radiotherapy resistance acquisition in Glioblastoma. Role of SOCS1 and SOCS3

Journal: PLoS ONE

doi: 10.1371/journal.pone.0212581

Molecular features of stablished GBM cell lines. Electropherograms of IDH1 (a , f , k , p, u, aa ), IDH2 ( b , g , l , q , w , ab ), and TERT ( c , h , m , r , x , ac ), and immunocytochemistry images of P53 ( d , i , n , s , y , ad ) and PTEN ( e , j , o , t , z , ae ) of all cell lines are shown. The first line corresponds to GB16, the second line to GB37, the third line to GB39, the fourth line to GB40, the fifth line to GB42 and the sixth line to GB48. Red rectangles show the codon which harbours the mutation. The images were made to 40ꓫ.
Figure Legend Snippet: Molecular features of stablished GBM cell lines. Electropherograms of IDH1 (a , f , k , p, u, aa ), IDH2 ( b , g , l , q , w , ab ), and TERT ( c , h , m , r , x , ac ), and immunocytochemistry images of P53 ( d , i , n , s , y , ad ) and PTEN ( e , j , o , t , z , ae ) of all cell lines are shown. The first line corresponds to GB16, the second line to GB37, the third line to GB39, the fourth line to GB40, the fifth line to GB42 and the sixth line to GB48. Red rectangles show the codon which harbours the mutation. The images were made to 40ꓫ.

Techniques Used: Immunocytochemistry, Mutagenesis

Related Articles

Affinity Purification:

Article Title: Disruption of the COP9 Signalosome Csn2 Subunit in Mice Causes Deficient Cell Proliferation, Accumulation of p53 and Cyclin E, and Early Embryonic Death
Article Snippet: For antibody staining, the sections were deparaffinized and placed into a 3% solution of hydrogen peroxide for 5 min. After incubation with the primary antibodies for 1 h followed by washing, biotinylated secondary antibody was applied for 30 min and streptavidin-horseradish peroxidase was applied for 30 min. Diaminobenzidine was used as the peroxidase substrate, and counterstaining was performed with hematoxylin. .. The antibodies used include anti-CSN2 (1:1,000), anti-CSN1 (1:100), and anti-CSN8 (affinity purified, 0.7 mg/ml, at 1:250) (Affiniti Research Inc.), anti-cyclin E (M-20 Santa Cruz, 1:150), anti-p53 (Dako), and anti-p21 (C-19 Santa Cruz, 1:250). .. Bromodeoxyuridine was added to culture media to a final concentration of 10 μM and incubated for 12 h at the time period specified.

Incubation:

Article Title: Clinicopathological Analysis of Factors Related to Colorectal Tumor Perforation
Article Snippet: Immunohistochemistry Immunohistochemistry was performed on formalin-fixed paraffin-embedded sections of tumor, after antigen retrieval in high pH solution (Dako), at 123_C for 1 min. .. Sections were treated with 0.1% Triton X-100 in phosphate buffered 170 saline (PBS), and then incubated with mouse monoclonal antibody, diluted 1:50 in 3% bovine serum albumin/PBS, against human VEGF human AB 1785 (Calbiochem Lab), mouse 172 anti-p53 mouse DO-7 anti-p53 (Dako Lab) and mouse anti CD31 mouse JC-70 A (Dako Lab). .. After blocking endogenous peroxidase with 0.3% H2 O2 in methanol, for 15 min., slides were washed 3 times, 5 min each, with PBS and then incubated for 30 min with Horseradich Peroxidase-conjugated anti-mouse IgG serum (Dako).

SDS Page:

Article Title: HIPK1 drives p53 activation to limit colorectal cancer cell growth
Article Snippet: Immunoprecipitation experiments were performed using the FLAG® Immunoprecipitation Kit (Sigma-Aldrich). .. All lysates were electrophoresed in a 10% SDS-PAGE, and transferred to PVDF membranes for immunoblotting with the appropriate primary antibody according the manufacturer’s instructions: anti-HIPK1 antibody (AP7137a, Abgent); anti-p53 antibody (DO-7 Ab; Dako); anti-serine 15 p53 antibody (Cell Signaling Technology); anti-p21 antibody (Cell Signaling); anti-Flag antibody (F7425, SIGMA). .. Membranes were then rinsed, incubated with the corresponding horseradish peroxidase-conjugated anti-mouse or anti-rabbit antibody (GE Healthcare Lifescience), and developed with ECL western blotting detection system (GE Healthcare Lifescience).

Immunohistochemistry:

Article Title: O6-methylguanine-DNA methyltransferase is downregulated in transformed astrocyte cells: implications for anti-glioma therapies
Article Snippet: Histological analysis and immunohistochemistry Formalin-fixed paraffin-embedded tissues were sectioned and stained with haematoxylin and eosin (H & E) using standard protocols. .. Immunohistochemistry was performed using anti-Ki-67 (MIB-1; Dako, Glostrup, Denmark) and anti-p53 (DO-7; Dako) monoclonal antibodies. .. Immunoblotting Protein determination, SDS-PAGE and immunoblotting were carried out as described previously [ ], and reactive protein signals were visualized by chemiluminescence using the ECL reagent (Amersham, Piscataway, NJ, USA) or the SuperSignal West Femto reagent (Pierce, Rockford, IL, USA).

Similar Products

  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 86
    Agilent technologies mouse anti human p53
    TFPI2 is upregulated by P14ARF in a <t>P53</t> independent manner
    Mouse Anti Human P53, supplied by Agilent technologies, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/mouse anti human p53/product/Agilent technologies
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    mouse anti human p53 - by Bioz Stars, 2021-04
    86/100 stars
      Buy from Supplier

    99
    Agilent technologies mouse monoclonal anti p53 antibody
    Prognostic impact of Ki67 labeling index (LI) and <t>p53</t> status in patients with hormone receptor-positive and HER2-negative breast cancer (n=142). A, Disease free survival curves for 98 patients with Ki67 LI-low tumors and 44 patients with Ki67 LI-high tumors. The 2 curves differ significantly (HR, 3.6; 95% CI, 1.7–7.9; log-rank P = 0.0004). B, Overall survival curves for 98 patients with Ki67 LI-low tumors and 44 patients with Ki67 LI-high tumors. The 2 curves differ significantly (HR, 4.4; 95% CI, 1.3–14.6; log-rank P = 0.0082). C , Disease-free survival curves for 122 patients with p53-negative tumors and 20 patients with p53-positive tumors. The 2 curves differ significantly (HR, 5.2; 95% CI, 2.3–11.9; log-rank P
    Mouse Monoclonal Anti P53 Antibody, supplied by Agilent technologies, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/mouse monoclonal anti p53 antibody/product/Agilent technologies
    Average 99 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    mouse monoclonal anti p53 antibody - by Bioz Stars, 2021-04
    99/100 stars
      Buy from Supplier

    97
    Agilent technologies anti p53
    Functional relationship between IL-6/STAT3 and <t>p53</t> signaling pathways including a mechanism for miRNA-mediated CDX2 suppression. (A) RT-qPCR analysis of CDX2 expression in 8 gastric cancer cell lines. (B) RT-qPCR analysis of CDX2 mRNA expression. CDX2 was suppressed by pre-miR-181b transfection in KATOIII and MKN74 cells. *P
    Anti P53, supplied by Agilent technologies, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti p53/product/Agilent technologies
    Average 97 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    anti p53 - by Bioz Stars, 2021-04
    97/100 stars
      Buy from Supplier

    Image Search Results


    TFPI2 is upregulated by P14ARF in a P53 independent manner

    Journal: Cancer research

    Article Title: p14ARF suppresses tumor-induced thrombosis by regulating the tissue factor pathway

    doi: 10.1158/0008-5472.CAN-13-1951

    Figure Lengend Snippet: TFPI2 is upregulated by P14ARF in a P53 independent manner

    Article Snippet: The membranes were immunoblotted using polyclonal rabbit anti-HA or goat anti-p14ARF antibodies to detect p14ARF (1:2,000 dilution, Covance; 1:1000, Santa Cruz Biotechnologies), mouse anti-human p53 (clone DO-7; 1:1,000, DAKO), mouse anti-human p21 (Ab-11; 1:500, NeoMarkers), rabbit anti-SP1 (1:500, PEP2), goat anti- β -Actin (1:1,000) and mouse anti- α -Tubulin (1:500) (Santa Cruz Biotechnologies); rabbit anti-c-JUN, anti-Phospho S63 and S73 c-JUN, anti-JNK1/2 (1:500, Cell Signaling Technologies), anti-JNK (1:300, Zymed), rabbit anti-TFPI2 (generously provided by Dr. Walter Kisiel, Krakow, Poland) and mouse anti-TFPI2 (B7) (Santa Cruz Biotechnologies).

    Techniques:

    Prognostic impact of Ki67 labeling index (LI) and p53 status in patients with hormone receptor-positive and HER2-negative breast cancer (n=142). A, Disease free survival curves for 98 patients with Ki67 LI-low tumors and 44 patients with Ki67 LI-high tumors. The 2 curves differ significantly (HR, 3.6; 95% CI, 1.7–7.9; log-rank P = 0.0004). B, Overall survival curves for 98 patients with Ki67 LI-low tumors and 44 patients with Ki67 LI-high tumors. The 2 curves differ significantly (HR, 4.4; 95% CI, 1.3–14.6; log-rank P = 0.0082). C , Disease-free survival curves for 122 patients with p53-negative tumors and 20 patients with p53-positive tumors. The 2 curves differ significantly (HR, 5.2; 95% CI, 2.3–11.9; log-rank P

    Journal: BMC Clinical Pathology

    Article Title: A simple immunohistochemical panel comprising 2 conventional markers, Ki67 and p53, is a powerful tool for predicting patient outcome in luminal-type breast cancer

    doi: 10.1186/1472-6890-13-5

    Figure Lengend Snippet: Prognostic impact of Ki67 labeling index (LI) and p53 status in patients with hormone receptor-positive and HER2-negative breast cancer (n=142). A, Disease free survival curves for 98 patients with Ki67 LI-low tumors and 44 patients with Ki67 LI-high tumors. The 2 curves differ significantly (HR, 3.6; 95% CI, 1.7–7.9; log-rank P = 0.0004). B, Overall survival curves for 98 patients with Ki67 LI-low tumors and 44 patients with Ki67 LI-high tumors. The 2 curves differ significantly (HR, 4.4; 95% CI, 1.3–14.6; log-rank P = 0.0082). C , Disease-free survival curves for 122 patients with p53-negative tumors and 20 patients with p53-positive tumors. The 2 curves differ significantly (HR, 5.2; 95% CI, 2.3–11.9; log-rank P

    Article Snippet: The antibodies used were mouse monoclonal anti-p53 antibody (DO-7, Dako, Glostrup, Denmark), mouse monoclonal anti-Ki67 antibody (MIB-1, Dako), mouse monoclonal anti-FOXA1 antibody (2D7, Abnova, Taipei, Taiwan), mouse monoclonal anti-GATA3 antibody (HG3-31, Santa Cruz, Santa Cruz, CA, USA) mouse monoclonal anti-CK5/6 antibody (D5/16 B4, Dako), mouse monoclonal anti-CK14 antibody (LL002, NeoMarkers, Fremont, CA, USA), mouse monoclonal anti-P-cadherin antibody (56C1, Novocastra, Newcastle, UK), and a mouse monoclonal anti-EGFR antibody included in an EGFR pharmDX kit (Dako).

    Techniques: Labeling

    Representative images of immunostaining for 9 molecular markers. A , Positive nuclear Ki67 staining. The Ki67 labeling index of this specimen is 12%. B , p53 staining in the nucleus. This tumor was scored as p53-positive. C , Positive HER2 membrane staining. The HER2 expression of this tumor was scored as 3+. D , Positive nuclear FOXA1 staining. This tumor was classified as FOXA1-positive. E , Positive nuclear GATA3 staining. This tumor was classified as GATA3-positive. F , Positive CK5/6 membrane or sub-membrane staining of tumor cells. This tumor was classified as CK5/6-positive. G , Positive CK14 membrane or sub-membrane staining of tumor cells. This tumor was classified as CK14-positive. H , Positive EGFR membrane staining of tumor cells. The EGFR expression of this tumor was scored as 3+. I , Positive P-cadherin membrane or sub-membrane immunoreactivity of tumor cells. This tumor was classified as P-cadherin-high. The magnification of all figures is ×400.

    Journal: BMC Clinical Pathology

    Article Title: A simple immunohistochemical panel comprising 2 conventional markers, Ki67 and p53, is a powerful tool for predicting patient outcome in luminal-type breast cancer

    doi: 10.1186/1472-6890-13-5

    Figure Lengend Snippet: Representative images of immunostaining for 9 molecular markers. A , Positive nuclear Ki67 staining. The Ki67 labeling index of this specimen is 12%. B , p53 staining in the nucleus. This tumor was scored as p53-positive. C , Positive HER2 membrane staining. The HER2 expression of this tumor was scored as 3+. D , Positive nuclear FOXA1 staining. This tumor was classified as FOXA1-positive. E , Positive nuclear GATA3 staining. This tumor was classified as GATA3-positive. F , Positive CK5/6 membrane or sub-membrane staining of tumor cells. This tumor was classified as CK5/6-positive. G , Positive CK14 membrane or sub-membrane staining of tumor cells. This tumor was classified as CK14-positive. H , Positive EGFR membrane staining of tumor cells. The EGFR expression of this tumor was scored as 3+. I , Positive P-cadherin membrane or sub-membrane immunoreactivity of tumor cells. This tumor was classified as P-cadherin-high. The magnification of all figures is ×400.

    Article Snippet: The antibodies used were mouse monoclonal anti-p53 antibody (DO-7, Dako, Glostrup, Denmark), mouse monoclonal anti-Ki67 antibody (MIB-1, Dako), mouse monoclonal anti-FOXA1 antibody (2D7, Abnova, Taipei, Taiwan), mouse monoclonal anti-GATA3 antibody (HG3-31, Santa Cruz, Santa Cruz, CA, USA) mouse monoclonal anti-CK5/6 antibody (D5/16 B4, Dako), mouse monoclonal anti-CK14 antibody (LL002, NeoMarkers, Fremont, CA, USA), mouse monoclonal anti-P-cadherin antibody (56C1, Novocastra, Newcastle, UK), and a mouse monoclonal anti-EGFR antibody included in an EGFR pharmDX kit (Dako).

    Techniques: Immunostaining, Staining, Labeling, Expressing

    Prognostic impact of combined Ki67-p53 status in patients with hormone receptor-positive and HER2-negative breast cancer (n=142) . A, Disease-free survival curves for 88 patients with Ki67 LI-low and p53-negative tumors, 34 patients with Ki67 LI-high and p53-negative tumors, 10 patients with Ki67 LI-low and p53-positive tumors, and 10 patients with Ki67 LI-high and p53-positive tumors. Patients with Ki67 LI-low and p53-negative tumors had significantly longer disease-free survival than those with Ki67 LI-low and p53-positive tumors, those with Ki67 LI-high and p53-negative tumors, or those with Ki67 LI-high and p53-positive tumors ( P

    Journal: BMC Clinical Pathology

    Article Title: A simple immunohistochemical panel comprising 2 conventional markers, Ki67 and p53, is a powerful tool for predicting patient outcome in luminal-type breast cancer

    doi: 10.1186/1472-6890-13-5

    Figure Lengend Snippet: Prognostic impact of combined Ki67-p53 status in patients with hormone receptor-positive and HER2-negative breast cancer (n=142) . A, Disease-free survival curves for 88 patients with Ki67 LI-low and p53-negative tumors, 34 patients with Ki67 LI-high and p53-negative tumors, 10 patients with Ki67 LI-low and p53-positive tumors, and 10 patients with Ki67 LI-high and p53-positive tumors. Patients with Ki67 LI-low and p53-negative tumors had significantly longer disease-free survival than those with Ki67 LI-low and p53-positive tumors, those with Ki67 LI-high and p53-negative tumors, or those with Ki67 LI-high and p53-positive tumors ( P

    Article Snippet: The antibodies used were mouse monoclonal anti-p53 antibody (DO-7, Dako, Glostrup, Denmark), mouse monoclonal anti-Ki67 antibody (MIB-1, Dako), mouse monoclonal anti-FOXA1 antibody (2D7, Abnova, Taipei, Taiwan), mouse monoclonal anti-GATA3 antibody (HG3-31, Santa Cruz, Santa Cruz, CA, USA) mouse monoclonal anti-CK5/6 antibody (D5/16 B4, Dako), mouse monoclonal anti-CK14 antibody (LL002, NeoMarkers, Fremont, CA, USA), mouse monoclonal anti-P-cadherin antibody (56C1, Novocastra, Newcastle, UK), and a mouse monoclonal anti-EGFR antibody included in an EGFR pharmDX kit (Dako).

    Techniques:

    Immunohistochemical staining for p53 in an esophageal squamous cell carcinoma exhibiting expression. A: With primary antibody, showing reactivity (brown nuclear staining of some tumor cells) (× 100); B: With primary antibody, showing reactivity (× 400); C: With primary antibody, no reactivity (× 100). Sections were counter-stained with hematoxylin.

    Journal: World Journal of Gastroenterology : WJG

    Article Title: Association of p53/p21 expression with cigarette smoking and prognosis in esophageal squamous cell carcinoma patients

    doi: 10.3748/wjg.v16.i39.4958

    Figure Lengend Snippet: Immunohistochemical staining for p53 in an esophageal squamous cell carcinoma exhibiting expression. A: With primary antibody, showing reactivity (brown nuclear staining of some tumor cells) (× 100); B: With primary antibody, showing reactivity (× 400); C: With primary antibody, no reactivity (× 100). Sections were counter-stained with hematoxylin.

    Article Snippet: After blocking the nonspecific protein binding with serum-free protein block (Dako, Inc.) for 5 min, slides were incubated for 45 min at 37°C with either anti-human p21waf1/cip1 monoclonal antibody (clone SX118, DAKO, CA, USA; dilution 1:50) or anti-p53 monoclonal antibody (clone DO-7; DAKO, CA, USA; dilution 1:50) DO-7 which was raised against an epitope between amino acids 1 and 45 in the C-terminal domain of human wild-type and mutant p53 recognizing both mutant and wild-type p53 protein, followed by phosphate buffered saline wash.

    Techniques: Immunohistochemistry, Staining, Expressing

    Functional relationship between IL-6/STAT3 and p53 signaling pathways including a mechanism for miRNA-mediated CDX2 suppression. (A) RT-qPCR analysis of CDX2 expression in 8 gastric cancer cell lines. (B) RT-qPCR analysis of CDX2 mRNA expression. CDX2 was suppressed by pre-miR-181b transfection in KATOIII and MKN74 cells. *P

    Journal: Oncology Letters

    Article Title: CDX2 is involved in microRNA-associated inflammatory carcinogenesis in gastric cancer

    doi: 10.3892/ol.2017.6956

    Figure Lengend Snippet: Functional relationship between IL-6/STAT3 and p53 signaling pathways including a mechanism for miRNA-mediated CDX2 suppression. (A) RT-qPCR analysis of CDX2 expression in 8 gastric cancer cell lines. (B) RT-qPCR analysis of CDX2 mRNA expression. CDX2 was suppressed by pre-miR-181b transfection in KATOIII and MKN74 cells. *P

    Article Snippet: Following rinsing in PBS, the sections were incubated with anti-CDX2 antibody (1:1,000; cat. no. MU392A-UC; clone CDX2-88, Biogenex, San Ramon, CA, USA) and anti-p53 (1:1,000; cat. no. M7000101-2; DO-7, Dako; Agilent Technologies, Inc.) at 4°C overnight.

    Techniques: Functional Assay, Quantitative RT-PCR, Expressing, Transfection